Leerink Partnrs reissued their outperform rating on shares of LENZ Therapeutics (NASDAQ:LENZ - Free Report) in a research note issued to investors on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics' Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.
Other analysts have also issued reports about the stock. Citigroup started coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They issued a buy rating and a $34.00 price objective on the stock. Piper Sandler started coverage on shares of LENZ Therapeutics in a research report on Wednesday, March 27th. They issued an overweight rating and a $28.00 price objective on the stock. William Blair initiated coverage on shares of LENZ Therapeutics in a research report on Monday. They issued an outperform rating on the stock. Finally, SVB Leerink initiated coverage on shares of LENZ Therapeutics in a research note on Monday. They issued an outperform rating and a $32.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $31.33.
Check Out Our Latest Stock Analysis on LENZ Therapeutics
LENZ Therapeutics Price Performance
LENZ Therapeutics stock traded down $2.22 during midday trading on Monday, reaching $17.70. The stock had a trading volume of 84,141 shares, compared to its average volume of 58,431. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82. The firm has a market capitalization of $147.26 million, a P/E ratio of -1.13 and a beta of 0.20.
Insiders Place Their Bets
In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the company's stock in a transaction dated Thursday, March 21st. The shares were purchased at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the purchase, the director now owns 3,319,339 shares in the company, valued at $49,889,665.17. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 38.40% of the company's stock.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
